New Study Raises More Questions About J&J COVID Vaccine
New Study Raises More Questions About J&J COVID Vaccine
The Delta variant is now responsible for 83% of new COVID cases in the U.S. Now, a preliminary study not yet peer reviewed suggests the Johnson & Johnson vaccine may not be as effective against the variant as Modern and Pfizer.
CBS2's Dr. Max Gomez explains.